Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03101475
Title Synergism of Immunomodulation and Tumor Ablation (ILOC)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors European Organisation for Research and Treatment of Cancer - EORTC

colorectal cancer


Durvalumab + Tremelimumab

Age Groups: senior | adult
Covered Countries FRA | DEU | AUT

No variant requirements are available.